Allogeneic Bone Marrow Transplantation in Patients With Primary Immunodeficiencies
Public ClinicalTrials.gov record NCT00006054. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
OBJECTIVES: I. Provide curative immunoreconstituting allogeneic bone marrow transplantation for patients with primary immunodeficiencies. II. Determine relevant outcomes of this treatment in these patients including quality of survival, extent of morbidity and mortality from complications of the treatment (e.g., graft versus host disease, regimen related toxicities, B- cell lymphoproliferative disease), and completeness of functional immunoreconstitution.
Study identification
- NCT ID
- NCT00006054
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Not applicable
- Enrollment
- Not listed
Conditions and interventions
Conditions
- Immunologic Deficiency Syndromes
- Chediak-Higashi Syndrome
- Common Variable Immunodeficiency
- Graft Versus Host Disease
- X-Linked Lymphoproliferative Syndrome
- Familial Erythrophagocytic Lymphohistiocytosis
- Hemophagocytic Lymphohistiocytosis
- X-linked Agammaglobulinemia
- Wiskott-Aldrich Syndrome
- Chronic Granulomatous Disease
- X-linked Hyper IgM Syndrome
- Severe Combined Immunodeficiency
- Leukocyte Adhesion Deficiency Syndrome
- Virus-Associated Hemophagocytic Syndrome
Interventions
- anti-thymocyte globulin Drug
- busulfan Drug
- cyclophosphamide Drug
- cyclosporine Drug
- etoposide Drug
- methotrexate Drug
- methylprednisolone Drug
- prednisone Drug
- Allogeneic Bone Marrow Transplantation Procedure
Drug · Procedure
Eligibility (public fields only)
- Age range
- Up to 35 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Feb 29, 2000
- Primary completion
- Nov 30, 2002
- Completion
- Nov 30, 2002
- Last update posted
- Oct 14, 2009
2000 – 2002
United States locations
- U.S. sites
- 1
- U.S. states
- 1
- U.S. cities
- 1
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Fairview University Medical Center | Minneapolis | Minnesota | 55455 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00006054, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Oct 14, 2009 · Synced Sep 5, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00006054 live on ClinicalTrials.gov.